keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/28538494/committee-opinion-no-704-summary-human-papillomavirus-vaccination
#1
(no author information available yet)
Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and genital warts. Despite the benefits of HPV vaccines, only 41.9% of girls in the recommended age group, and only 28.1% of males in the recommended age group have received all recom-mended doses. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low...
June 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28512072/lessons-learnt-in-japan-from-adverse-reactions-to-the-hpv-vaccine-a-medical-ethics-perspective
#2
Hirokuni Beppu, Masumi Minaguchi, Kiyoshi Uchide, Kunihiko Kumamoto, Masato Sekiguchi, Yukari Yaju
The human papillomavirus (HPV) vaccine has been linked to a number of serious adverse reactions. The range of symptoms is diverse and they develop in a multi-layered manner over an extended period of time. The argument for the safety and effectiveness of the HPV vaccine overlooks the following flaws: (i) no consideration is given to the genetic basis of autoimmune diseases, and arguments that do not take this into account cannot assure the safety of the vaccine; (ii) the immune evasion mechanisms of HPV, which require the HPV vaccine to maintain an extraordinarily high antibody level for a long period of time for it to be effective, are disregarded; and (iii) the limitations of effectiveness of the vaccine...
April 2017: Indian Journal of Medical Ethics
https://www.readbyqxmd.com/read/28503996/primary-immunization-of-human-papillomavirus-vaccine-in-the-pediatric-population-what-is-the-verdict-now
#3
Aubrey N Jones, Jenna W Bartlett, Rebecca A Bates, Tsz-Yin So
The safety and efficacy of a 2-dose series for the human papillomavirus vaccines rather than a 3-dose series in older children has not been well defined. This article reviews the literature summarizing the use of all 3 HPV vaccines (2vHPV, 4vHPV, 9vHPV) as a 2-dose series for females and 4vHPV and 9vHPV for males younger than 15 years. Six prospective trials evaluating immunogenicity of a 2-dose series of 2vHPV and/or 4vHPV, as well as an ongoing prospective clinical trial for 9vHPV, are discussed. The 2-dose series with Gardasil 9(®) in both males and females ages 9 to 14 years appears to be the most widely accepted recommendation...
June 2017: Clinical Pediatrics
https://www.readbyqxmd.com/read/28492521/coinjection-of-il2-dna-enhances-e7-specific-antitumor-immunity-elicited-by-intravaginal-therapeutic-hpv-dna-vaccination-with-electroporation
#4
Y Sun, S Peng, A Yang, E Farmer, T-C Wu, Chien-Fu Hung
The generation and use of therapeutic human papillomavirus (HPV) DNA vaccines represent an appealing treatment method against HPV-associated cervical cancer due to their safety and durability. Previously, we created a therapeutic HPV DNA vaccine candidate by linking the HPV16-E7 DNA sequence to calreticulin (CRT/E7), which we showed could generate significant E7-specific cytotoxic T lymphocyte (CTL)-mediated anti-tumor immune responses against HPV16 oncogenes expressing murine tumor model TC-1. Here we assess the therapeutic efficacy of intravaginal immunization with pcDNA3-CRT/E7 followed by electroporation...
May 11, 2017: Gene Therapy
https://www.readbyqxmd.com/read/28487749/highlights-from-the-first-ecancer-liga-colombiana-contra-el-cancer-conference-17-18-november-2016-bogota-colombia
#5
Carlos Castro
The first oncology conference organised by ecancer and the Liga Colombiana contra el Cancer took place on 17-18 November 2016 in Bogota. It was a highly successful event owing to the number of participants, the quality of the speakers, and the academic programme. Around 48 professors from 8 different countries came and shared their knowledge and experience of cancer management. They also talked about the most recent developments noted or achieved in this area. The keynote speech from Dr Nubia Muñoz was of great interest which was related to the safety of a HPV vaccine and the implications of a mass vaccination programme in developing countries...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28461067/mapping-information-exposure-on-social-media-to-explain-differences-in-hpv-vaccine-coverage-in-the-united-states
#6
Adam G Dunn, Didi Surian, Julie Leask, Aditi Dey, Kenneth D Mandl, Enrico Coiera
BACKGROUND: Together with access, acceptance of vaccines affects human papillomavirus (HPV) vaccine coverage, yet little is known about media's role. Our aim was to determine whether measures of information exposure derived from Twitter could be used to explain differences in coverage in the United States. METHODS: We conducted an analysis of exposure to information about HPV vaccines on Twitter, derived from 273.8 million exposures to 258,418 tweets posted between 1 October 2013 and 30 October 2015...
April 28, 2017: Vaccine
https://www.readbyqxmd.com/read/28457055/short-term-efficacy-of-cbd-enriched-hemp-oil-in-girls-with-dysautonomic-syndrome-after-human-papillomavirus-vaccination
#7
Beniamino Palmieri, Carmen Laurino, Maria Vadalà
BACKGROUND: Cannabidiol (CBD)-based treatments for several diseases, including Tourette's syndrome, multiple sclerosis, epilepsy, movement disorders and glaucoma, are proving to be beneficial and the scientific clinical background of the drug is continuously evolving. OBJECTIVES: To investigate the short-term effect of CBD-enriched hemp oil for relieving symptoms and improving the life quality (QOL) in young girls with adverse drug effects (ADRs) following human papillomavirus (HPV) vaccine...
February 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28455577/-one-decade-of-hpv-vaccination-in-germany
#8
REVIEW
P Schneede
As a worldwide very common sexually transmitted infection (STI), HPV causes millions of genital warts every year and is responsible for 5% of all cancers in men and women. With strong empirical evidence for both vaccine safety and efficacy, the HPV vaccines proved to protect against these HPV-related conditions over the last decade. But current HPV vaccination coverage is suboptimal in many countries. Even in Germany the absence of a school-based immunization program and the recommendation of a publicly funded girls-only HPV vaccination strategy are the main reasons for a female coverage rate under 40%, which does not achieve herd immunity for the boys...
April 28, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28451790/hpv16-e7-dna-tattooing-safety-immunogenicity-and-clinical-response-in-patients-with-hpv-positive-vulvar-intraepithelial-neoplasia
#9
Sanne Samuels, A Marijne Heeren, Henry J M A A Zijlmans, Marij J P Welters, Joost H van den Berg, Daisy Philips, Pia Kvistborg, Ilina Ehsan, Suzy M E Scholl, Bastiaan Nuijen, Ton N M Schumacher, Marc van Beurden, Ekaterina S Jordanova, John B A G Haanen, Sjoerd H van der Burg, Gemma G Kenter
BACKGROUND: Usual type vulvar intraepithelial neoplasia (uVIN) is caused by HPV, predominantly type 16. Several forms of HPV immunotherapy have been studied, however, clinical results could be improved. A novel intradermal administration route, termed DNA tattooing, is superior in animal models, and was tested for the first time in humans with a HPV16 E7 DNA vaccine (TTFC-E7SH). METHODS: The trial was designed to test safety, immunogenicity, and clinical response of TTFC-E7SH in twelve HPV16(+) uVIN patients...
April 27, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28446260/human-papillomavirus-9-valent-vaccine-for-cancer-prevention-a-systematic-review-of-the-available-evidence
#10
C Signorelli, A Odone, V Ciorba, P Cella, R A Audisio, A Lombardi, L Mariani, F S Mennini, S Pecorelli, G Rezza, G V Zuccotti, A Peracino
In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also targeted by the quadrivalent HPV vaccine (qHPV), plus five additional high cancer risk HPV types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the literature on 9vHPV efficacy, immunogenicity and safety, as well as a systematic search of registered, completed, and ongoing RCTs...
April 27, 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28419156/school-nurses-attitudes-towards-and-experiences-of-the-swedish-school-based-hpv-vaccination-programme-a-repeated-cross-sectional-study
#11
Maria Grandahl, Margareta Larsson, Tanja Tydén, Christina Stenhammar
The aim was to investigate school nurses' attitudes towards, and experiences of vaccination against human papillomavirus (HPV), and compare the results with a similar study three years earlier. School nurses (n = 736) from all counties in Sweden completed a questionnaire in spring 2016, four years after the implementation of the national HPV vaccination programme, and three years after the previous survey. Overall, the school nurses had more favourable attitudes towards the HPV vaccination programme compared to the study in 2013 (p = 0...
2017: PloS One
https://www.readbyqxmd.com/read/28404357/the-safety-and-immunogenicity-of-quadrivalent-hpv-qhpv-vaccine-in-systemic-lupus-erythematosus
#12
J Patricia Dhar, Lynnette Essenmacher, Renee Dhar, Ardella Magee, Joel Ager, Robert J Sokol
OBJECTIVE: This study evaluated the safety and immunogenicity of qHPV vaccine in SLE. METHODS: Subjects: 34 women ages 19-50years (yrs.) with mild to moderate SLE & minimally active or inactive SLE received qHPV vaccine at the standard dosing schedule. EXCLUSION CRITERIA: active SLE disease (SELENA-SLEDAI>2), history of severe SLE disease, deep venous thrombosis, on >400mg/day of hydroxychloroquine, on >15mg/day of prednisone, or active infections...
May 9, 2017: Vaccine
https://www.readbyqxmd.com/read/28359835/reasons-for-non-initiation-and-non-completion-of-hpv-vaccine-among-english-and-spanish-speaking-parents-of-adolescent-girls-a-qualitative-study
#13
Karen Albright, Juliana Barnard, Sean O'Leary, Steven Lockhart, Andrea Jimenez-Zambrano, Shannon Stokley, Amanda Dempsey, Allison Kempe
OBJECTIVE: The Advisory Committee on Immunization Practices recommends routine human papillomavirus (HPV) vaccination for females aged 11-12 years, yet vaccination rates remain low. We conducted a qualitative study to understand English- and Spanish-speaking parents' reasons for non-initiation or non-completion of the HPV vaccine series for their daughters. METHODS: Parents of females aged 12-15 years who had not initiated or not completed the HPV vaccine series were identified through administrative data in two large urban safety net health care systems in Colorado...
March 27, 2017: Academic Pediatrics
https://www.readbyqxmd.com/read/28355499/quadrivalent-hpv-vaccination-and-the-risk-of-adverse-pregnancy-outcomes
#14
Nikolai M Scheller, Björn Pasternak, Ditte Mølgaard-Nielsen, Henrik Svanström, Anders Hviid
BACKGROUND: The quadrivalent human papillomavirus (HPV) vaccine is recommended for all girls and women 9 to 26 years of age. Some women will have inadvertent exposure to vaccination during early pregnancy, but few data exist regarding the safety of the quadrivalent HPV vaccine in this context. METHODS: We assessed a cohort that included all the women in Denmark who had a pregnancy ending between October 1, 2006, and November 30, 2013. Using nationwide registers, we linked information on vaccination, adverse pregnancy outcomes, and potential confounders among women in the cohort...
March 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28346275/committee-opinion-no-704-human-papillomavirus-vaccination
#15
(no author information available yet)
Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and genital warts. Despite the benefits of HPV vaccines, only 41.9% of girls in the recommended age group, and only 28.1% of males in the recommended age group have received all recom-mended doses. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low...
June 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28337085/duty-to-advocate-human-papillomavirus-vaccination
#16
Kristen Nichols, Jennifer Girotto, Amy Mitchell-Van Steele, Sylvia Stoffella
Despite the excellent benefit-to-risk ratio for human papillomavirus (HPV) vaccination and recommendations for its routine use from the Advisory Committee on Immunization Practices (ACIP), significant controversy surrounding HPV vaccination continues to exist. In light of this controversy and continued low rates of vaccination among U.S. adolescents, the Pediatric Pharmacy Advocacy Group (PPAG) endorses the safety and efficacy of HPV vaccination and agrees with ACIP recommendations for protection of the U.S...
January 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/28328521/human-papillomavirus-first-and-second-generation-vaccines-current-status-and-future-directions
#17
Somayeh Pouyanfard, Martin Müller
It has been more than 10 years that the first prophylactic papillomavirus vaccine became available, although distribution has been mainly limited to the more affluent countries. The first two vaccines have been a great success, hundreds of millions of women and a much smaller number of men have been vaccinated ever since. In a few countries with high vaccination coverage, in particular Australia but also parts of Great Britain and others, clinical impact of vaccination programs is already visible and there are indications for herd immunity as well...
March 22, 2017: Biological Chemistry
https://www.readbyqxmd.com/read/28319456/reactogenicity-of-cervarix-and-gardasil-human-papillomavirus-hpv-vaccines-in-a-randomized-single-blind-trial-in-healthy-uk-adolescent-females
#18
Tao Haskins-Coulter, Jo Southern, Nick Andrews, Elizabeth Miller
One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in the national vaccination schedule at the time. Participants were blinded to treatment group until all 3 vaccinations had been given, while laboratory staff were masked during testing. For the majority of local and general reactions, recipients of both vaccines reported comparable frequencies...
March 20, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28266092/six-year-multi-centre-observational-post-marketing-surveillance-of-the-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-women-aged-10-25%C3%A2-years-in-korea
#19
Chul-Jung Kim, Rok Song, Jing Chen, Fernanda Taveres Da Silva, Kusuma B Gopala, Joon Hyung Kim, Dan Bi, Jong Sup Park
PURPOSE: To evaluate the safety of HPV-16/18 AS04-adjuvanted vaccine when administered as per the PI in Korea. METHODS: A total of 3084 women aged 10-25 years were enrolled in this post-marketing surveillance from 2008 to 2014. Subjects were invited to receive three doses of the vaccine (0, 1 and 6 months), and participants who received at least one dose were included in the analysis. Adverse events (AEs), adverse drug reactions (ADRs) and serious AEs (SAEs) were recorded after each dose...
March 7, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28193249/factors-associated-with-parental-reasons-for-no-intent-to-vaccinate-female-adolescents-with-human-papillomavirus-vaccine-national-immunization-survey-teen-2008-2012
#20
Vinay K Cheruvu, Madhav P Bhatta, Lauren N Drinkard
BACKGROUND: 1) To identify socio-demographic factors associated with parental "no-intent" for their 13-17 year old unvaccinated daughter to receive the human papillomavirus (HPV) vaccine series within the next twelve months, 2) to describe patterns in "no-intent" by socio-demographic factors, and 3) to identify socio-demographic factors associated with parental reasons for "no-intent". METHODS: Data from 2008-2012 National Immunization Survey - Teen (NIS - Teen) were examined in this study...
February 13, 2017: BMC Pediatrics
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"